M
Martina Willhauck-Fleckenstein
Researcher at German Cancer Research Center
Publications - 24
Citations - 803
Martina Willhauck-Fleckenstein is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 15, co-authored 24 publications receiving 655 citations. Previous affiliations of Martina Willhauck-Fleckenstein include Dartmouth College & University Hospital Heidelberg.
Papers
More filters
Journal ArticleDOI
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
Rengaswamy Sankaranarayanan,Priya R. Prabhu,Michael Pawlita,Tarik Gheit,Neerja Bhatla,Richard Muwonge,Bhagwan M. Nene,Pulikottil Okuru Esmy,Smita Joshi,Usha Rani Reddy Poli,Parimal Jivarajani,Yogesh Verma,Eric Zomawia,Maqsood Siddiqi,Surendra S Shastri,Kasturi Jayant,Sylla G. Malvi,Eric Lucas,Angelika Michel,Julia Butt,Janki Mohan Babu Vijayamma,Subha Sankaran,Thiraviam Pillai Rameshwari Ammal Kannan,Rintu Varghese,Uma Divate,Shila Thomas,Geeta Joshi,Martina Willhauck-Fleckenstein,Tim Waterboer,Martin Müller,Peter Sehr,Sanjay Hingmire,Alka Kriplani,Gauravi A Mishra,Sharmila Pimple,Radhika Jadhav,Catherine Sauvaget,Massimo Tommasino,Madhavan Radhakrishna Pillai +38 more
TL;DR: Despite the limitations imposed by the suspension of the HPV vaccination, the findings lend support to the WHO recommendation of two doses, at least 6 months apart, for routine vaccination of young girls.
Journal ArticleDOI
Seroepidemiology of Human Polyomaviruses in a US Population
Anala Gossai,Tim Waterboer,Heather H. Nelson,Angelika Michel,Martina Willhauck-Fleckenstein,Shohreh F. Farzan,Anne G. Hoen,Brock C. Christensen,Karl T. Kelsey,Carmen J. Marsit,Michael Pawlita,Margaret R. Karagas +11 more
TL;DR: It is suggested that PyV seropositivity is common in the United States and varies by sociodemographic and biological characteristics, including those related to immune function.
Journal ArticleDOI
Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer.
Aimée R. Kreimer,Mattias Johansson,Elizabeth L. Yanik,Hormuzd A. Katki,David P. Check,Krystle A. Lang Kuhs,Martina Willhauck-Fleckenstein,Dana Holzinger,Allan Hildesheim,Ruth M. Pfeiffer,Craig Williams,Neal D. Freedman,Wen-Yi Huang,Mark P. Purdue,Angelika Michel,Michael Pawlita,Paul Brennan,Tim Waterboer +17 more
TL;DR: Tumor analysis indicated that the sensitivity and specificity of HPV16-E6 antibodies were exceptionally high in predicting HPV-driven OPC, with stable antibody levels during annual follow-up for up to 13 years prior to diagnosis.
Journal ArticleDOI
Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study
Aimée R. Kreimer,Paul Brennan,Krystle A. Lang Kuhs,Tim Waterboer,Gary M. Clifford,Silvia Franceschi,Angelika Michel,Martina Willhauck-Fleckenstein,Elio Riboli,Xavier Castellsagué,Allan Hildesheim,Renée T. Fortner,Rudolf Kaaks,Domenico Palli,Ingrid Ljuslinder,Salvatore Panico,Franc¸oise Clavel-Chapelon,Franc¸oise Clavel-Chapelon,Franc¸oise Clavel-Chapelon,Marie-Christine Boutron-Ruault,Marie-Christine Boutron-Ruault,Marie-Christine Boutron-Ruault,Sylvie Mesrine,Sylvie Mesrine,Sylvie Mesrine,Antonia Trichopoulou,Pagona Lagiou,Pagona Lagiou,Pagona Lagiou,Dimitrios Trichopoulos,Dimitrios Trichopoulos,Petra H.M. Peeters,Amanda J. Cross,H. Bas Bueno-de-Mesquita,Paolo Vineis,Nerea Larrañaga,Valeria Pala,María José Sánchez,Carmen Navarro,Aurelio Barricarte,Rosario Tumino,Kay-Tee Khaw,Nicholas J. Wareham,Heiner Boeing,Annika Steffen,Ruth C. Travis,J. Ramón Quirós,Elisabete Weiderpass,Michael Pawlita,Mattias Johansson +49 more
TL;DR: HPV16 E6 seropositivity is relatively common before diagnosis of anal cancer but rare for other HPV-related anogenital cancers.
Journal ArticleDOI
Human Papillomavirus 16 E6 Antibodies in Individuals Without Diagnosed Cancer: A Pooled Analysis
Krystle A. Lang Kuhs,Devasena Anantharaman,Tim Waterboer,Mattias Johansson,Paul Brennan,Angelika Michel,Martina Willhauck-Fleckenstein,Mark P. Purdue,Mark P. Purdue,Ivana Holcatova,Wolfgang Ahrens,Pagona Lagiou,Jerry Polesel,Lorenzo Simonato,Franco Merletti,Claire M. Healy,Kristina Kjærheim,David I. Conway,Tatiana V. Macfarlane,Peter Thomson,Xavier Castellsagué,Ariana Znaor,Amanda Black,Wen Yi Huang,Vittorio Krogh,Antonia Trichopoulou,Antonia Trichopoulou,H. B. Bueno-De-Mesquita,Françoise Clavel-Chapelon,Françoise Clavel-Chapelon,Françoise Clavel-Chapelon,Elisabete Weiderpass,Johanna Ekström,Elio Riboli,Anne Tjønneland,María José Sánchez,Ruth C. Travis,Allan Hildesheim,Michael Pawlita,Aimée R. Kreimer +39 more
TL;DR: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors, especially those with seropositivity against other HPV16 proteins, which may harbor a biologically relevant HPV16 infection.